Biotech R&D, Reform, and Market Change

HEHS-95-34R: Published: Dec 15, 1994. Publicly Released: Dec 15, 1994.

Additional Materials:

Contact:

Office of Public Affairs
(202) 512-4800
youngc1@gao.gov

Pursuant to a congressional request, GAO reviewed the current state of biotechnology financing, focusing on the potential impact of health care reform on the biotechnology sector. GAO noted that: (1) biotech firms are typically small, have few if any products on the market, and are heavily dependent on outside financing for continued operations; (2) biotech firms are facing a cash crunch because investors have been reluctant to invest in biotech products due to disappointing clinical trials for once-promising biotech products; (3) investors have raised questions on how patent laws and health care reform will affect the future profitability of biotech firms; (4) in response to reduced resources, biotech firms have developed alliances with the pharmaceutical industry to provide additional financial and technical support; (5) legislation affecting the prescription drug market may affect the biotech industry directly and indirectly; and (6) if comprehensive health care reform legislation is enacted, the revenues from and demand for prescription drug products could increase or decrease depending on what cost controls are implemented.

Oct 15, 2018

Oct 1, 2018

Sep 28, 2018

Sep 17, 2018

Sep 13, 2018

Sep 10, 2018

Sep 6, 2018

Sep 5, 2018

Sep 4, 2018

Aug 24, 2018

Looking for more? Browse all our products here